Exclusive Summary

• Rebamipide Tablets are off-patent in major markets, offering significant generic entry opportunities, especially in high-prevalence gastrointestinal disease regions like Asia, Latin America, and the Middle East.
• With a lack of blockbuster drugs for primary gastric diseases (e.g., functional dyspepsia, peptic ulcers), rebamipide offers unique clinical value as a gastric mucosal protectant, supported by treatment guidelines.
• As a mature generic drug, it boasts significant cost advantages and multi-country registration experience, facilitating price approval and rapid market entry.
• The current global generic landscape is fragmented, allowing for differentiated competition, particularly for diseases requiring strong gastric mucosal repair.
• Chinese suppliers typically offer large-scale production and international quality standards (e.g., GMP), which are conducive to swift global market expansion.